Yamo Pharmaceuticals

    OverviewSuggest Edit

    Yamo Pharmaceuticals is a company developing L1-79, a therapy that targets the core symptoms of autism. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism, including socialization and communication.
    TypePrivate
    Websiteyamopharma.com

    Latest Updates

    Employees (est.) (Apr 2020)6
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Yamo Pharmaceuticals

    Chuck Bramlage

    Chuck Bramlage

    Chief Executive Officer
    Tom Megerian

    Tom Megerian

    Chief Medical Officer & Senior Vice President of Clinical Development
    John Rothman

    John Rothman

    Chief Scientific Advisor
    Eugene Prahin

    Eugene Prahin

    Chief Financial Officer
    Tracy Fischer

    Tracy Fischer

    Vice President – Regulatory Affairs & Quality
    Uyen Nguyen

    Uyen Nguyen

    Senior Director of Clinical Research Operations
    Show more

    Yamo Pharmaceuticals Online and Social Media Presence

    Embed Graph

    Yamo Pharmaceuticals Frequently Asked Questions

    • Who are Yamo Pharmaceuticals key executives?

      Yamo Pharmaceuticals's key executives are Chuck Bramlage, Tom Megerian and John Rothman.

    • How many employees does Yamo Pharmaceuticals have?

      Yamo Pharmaceuticals has 6 employees.

    • Who are Yamo Pharmaceuticals competitors?

      Competitors of Yamo Pharmaceuticals include PaxMedica, LianBio and Cells for Cells.